A multi-year, strategic relationship between Pfizer and Tempus, a provider of artificial intelligence (AI) and precision medicine, will advance the use of AI and machine learning in therapeutic research. The collaboration intends to more accurately gather information that will guide the development of new oncology drugs.
Under this partnership, Pfizer will have access to Tempus’ AI-enabled platform and its collection of de-identified, multimodal data to get insights for the advancement of therapeutics in the field of oncology. To advance its oncology portfolio, Pfizer has access to Tempus’ capabilities that support therapeutic R&D. These include AI-driven companion diagnostic offerings and Tempus’ clinical trial matching program, TIME, which quickly activates studies for patients in localities across the nation.
Founder and CEO of Tempus Eric Lefkofsky said, “Pfizer shares our dedication to bringing breakthrough treatments to patients faster, and we look forward to working together to usher in the next generation of oncology therapeutics. This is the third strategic partnership Tempus has forged with a major pharmaceutical company in the past year because, in our opinion, bringing together our technology prowess and pharma’s extensive R&D know-how will bring precision medicine much closer to its full potential.
